The Journal of Pharmacology and Experimental Therapeutics Highlighted Trainee Author for the August 2023 issue
Some highlights of the career of Dr Ronan Lordan
Some highlights of the career of Dr Ronan Lordan
Invitation to a dietary intervention study to assess the cardioprotective properties of a novel yoghurt drink.
If you are producing a food product with cardioprotective properties (e.g. kefir, cheese, yoghurt, fish, seafood), and you want to add value to your product, our team would be happy to discuss with you the possibilities of research funding towards the health-claims labeling of your product.
“Health claims” are going to be a game changer in the years to come and research data on the cardioprotective properties of your product is a safe way forward.
Antiplatelet therapies are discussed with a view to primary prevention of CVD by the clinical reduction of platelet reactivity and inflammation. Current antiplatelet therapies are effective in reducing cardiovascular risk but increase bleeding risk. Novel therapeutic antiplatelet approaches beyond current pharmacological modalities that do not increase the risk of bleeding require further investigation. There is potential for specifically designed nutraceuticals that may become safer alternatives to pharmacological antiplatelet agents for the primary prevention of CVD but there is serious concern over their efficacy and regulation, which requires considerably more research.
What I am trying to do with students is to give them guidelines to start writing an article as soon as possible when they start their PhD. Writing a paper makes them seeing the wider picture but it also guides them better into new experiments that they need to carry out. And the second thing that I always encourage them is to take part at the end of Year 1 of their PhDs at an international conference and present as a lecture (not as a poster!) their work. This experience makes them more confident in their work and confidence is a fundamental virtue in research.